JP2015535237A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535237A5
JP2015535237A5 JP2015538612A JP2015538612A JP2015535237A5 JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5 JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5
Authority
JP
Japan
Prior art keywords
composition
phosphate
citrate buffer
pharmaceutical composition
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535237A (ja
JP6431844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/059612 external-priority patent/WO2014064637A1/en
Publication of JP2015535237A publication Critical patent/JP2015535237A/ja
Publication of JP2015535237A5 publication Critical patent/JP2015535237A5/ja
Application granted granted Critical
Publication of JP6431844B2 publication Critical patent/JP6431844B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538612A 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物 Expired - Fee Related JP6431844B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1236KO2012 2012-10-26
IN1235/KOL/2012 2012-10-26
IN1235KO2012 2012-10-26
IN1236/KOL/2012 2012-10-26
PCT/IB2013/059612 WO2014064637A1 (en) 2012-10-26 2013-10-24 Stable pharmaceutical composition of tnfr:fc fusion protein

Publications (3)

Publication Number Publication Date
JP2015535237A JP2015535237A (ja) 2015-12-10
JP2015535237A5 true JP2015535237A5 (enExample) 2016-12-15
JP6431844B2 JP6431844B2 (ja) 2018-11-28

Family

ID=54208810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538612A Expired - Fee Related JP6431844B2 (ja) 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物

Country Status (14)

Country Link
US (2) US10058589B2 (enExample)
EP (1) EP2919801B1 (enExample)
JP (1) JP6431844B2 (enExample)
KR (1) KR102132050B1 (enExample)
CN (1) CN104936607A (enExample)
AU (1) AU2013336279B2 (enExample)
BR (1) BR112015009462A2 (enExample)
CA (1) CA2889271A1 (enExample)
ES (1) ES2806946T3 (enExample)
MX (1) MX366622B (enExample)
PL (1) PL2919801T3 (enExample)
PT (1) PT2919801T (enExample)
RU (1) RU2664691C2 (enExample)
WO (1) WO2014064637A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
MX2015015051A (es) * 2013-05-02 2016-06-10 Mabxience S A Formulaciones alternativas para polipeptidos de fusion tnfr:fc.
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
US20190060241A1 (en) * 2016-04-13 2019-02-28 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
WO2018075818A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
BR112020001363A2 (pt) * 2017-08-08 2020-08-11 Csl Behring Ag formulações de hemopexina
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
WO2022264097A1 (en) 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
IL135186A0 (en) * 1997-09-23 2001-05-20 Rentschler Biotechnologie Bmgh LIQUID INTERFERON-β FORMULATIONS
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP1603596B1 (en) 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
CA2724510C (en) * 2008-04-30 2015-10-27 Wockhardt Research Centre Processes for refolding of insulin
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
MX344727B (es) * 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc

Similar Documents

Publication Publication Date Title
JP2015535237A5 (enExample)
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
JP2019536761A5 (enExample)
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
JP2019504086A5 (enExample)
JP2012515221A5 (enExample)
JP2022166006A5 (enExample)
FI3209681T3 (fi) Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä
JP2010529999A5 (enExample)
RU2020112952A (ru) Жидкая фармацевтическая композиция
JP2013521296A5 (enExample)
JP2013543505A5 (enExample)
JP2011502968A5 (enExample)
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
RU2015132431A (ru) Составы, содержащие антитела
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
JP2019509311A5 (enExample)
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
RU2019116756A (ru) Жидкая фармацевтическая композиция
JP2016539921A5 (enExample)
JP2013543843A5 (enExample)
JP2015510882A5 (enExample)